Readily absorbed from the GI tract. Protein binding: 99%. Widely distributed. Metabolized in the liver to active metabolite. Primarily excreted in urine. Not removed by hemodialysis. Half-life: 22–30 hr.
! GI bleeding, gastritis, nephrotoxicity (dysuria, cystitis, hematuria, proteinuria, nephrotic syndrome), severe hepatic reactions (cholestasis, jaundice), and severe hypersensitivity reactions (bronchospasm, angioedema).
• Severe stomach bleeding may occur in patients who regularly use NSAIDs in recommended doses, when the patient is also taking another NSAID, a blood thinning, or steroid drug, if the patient has GI or peptic ulcer disease, if they are 60 yr or older, or when NSAIDs are taken longer than directed. Warn patients of the potential for severe stomach bleeding.
! Nadolol administration may precipitate CHF and MI in patients with cardiac disease; thyroid storm in those with thyrotoxicosis; and peripheral ischemia in those with existing peripheral vascular disease.
(100 mcg/ml strength) initial dose 0.25 mcg/kg followed by 0.25 mcg/kg, incremental dose at 2–5 min intervals; cumulative doses over 1.0 mcg/kg do not provide additional therapeutic effect; titrate all doses.
|Body weight (kg)||ml of 100 mcg/ml Solution|